Search

ENVISAGE – ENabling VISions And Growing Expectations

ENVISAGE is a validated evidence-based program of facilitated group workshops for parents and carers of young children, aged 0-8 years, with a newly identified disability or who have concerns regarding their child’s development.

Altered attainment of developmental milestones

Regression, including the loss of previously learned skills, such as hand function and communication skills, is one of the most suggestive features of Rett synd

Senior Research Officer, Fraser Mustard Centre, Adelaide

The Fraser Mustard Centre Adelaide is looking for a Senior Research Officer responsible for coordinating research on the Early Intervention Research Directorate

“It Was Such a Different Experience”: a Qualitative Study of Parental Perinatal Experiences When Having a Subsequent Child After Having a Child Diagnosed with Autism

Children who have an older sibling diagnosed with autism have an increased likelihood of being diagnosed with autism or developing broader developmental difficulties. This study explored perinatal experiences of parents of a child diagnosed with autism, spanning pre-conception until the subsequent child’s early developmental period.

The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial

Early supports to enhance social development in children with autism are widely promoted. While oxytocin has a crucial role in mammalian social development, its potential role as a medication to enhance social development in humans remains unclear.

Cystic Fibrosis

Cystic fibrosis (CF) is the most common life‐shortening genetic disease affecting children.

Short report: Care for children and adolescents with diabetes in Australia and New Zealand: Have we achieved the defined goals?

In 2010, the Australasian Paediatric Endocrinology Group formed a national Children's Diabetes Network that represented clinical teams managing over 95% of...

Amazing Adventurers raise $1.6M for research

The Telethon Adventurers have had another outstanding year, distributing more than $1.6 million for research into childhood brain tumours.

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

The MELODY Study is a Phase 3 randomized, double-blind, placebo-controlled, single-dose study to determine if MEDI8897 will prevent medically attended Respiratory Syncytial Virus (RSV) -confirmed Lower Respiratory Tract Infection (LRTI) in healthy infants entering their first RSV season.

A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)

The study is a phase 3, Multicentre, Randomised, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Health Infants.